Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

Jorgensen became CEO in January 2017 and the company’s market capitalization has more than tripled during his tenure. Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, but ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Popular weight loss drugs Ozempic and Wegovy would no longer be covered by Medi-Cal under a proposal unveiled by Gov. The costly drugs prescribed to fight obesity have been driving up the cost of Medi ...